Description of Business	6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 — Description of Business Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to orthotics and prosthetics (O&P) providers around the world, the Veterans Health Administration, and distributors in Europe and Australia. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts. Liquidity The Company incurred net losses of approximately $5.7 million and $5.6 million during the six months ended June 30, 2022 and 2021, respectively, and has an accumulated deficit of approximately $83.8 million and $78.1 million at June 30, 2022 and December 31, 2021, respectively. Cash used in operating activities was approximately $5.0 million and $5.5 million for the six months ended June 30, 2022 and 2021, respectively. The Company has historically funded its operations through financing activities, including raising equity and debt capital. The Company’s operating plans are primarily focused on scaling up its operations, increasing the proportion of patients carrying commercial insurance with payers that have historically reimbursed for the Company’s products and continued work with the Centers for Medicare and Medicaid Services, or CMS, and their administrative contractors regarding reimbursement of its products. In addition, the Company believes that it has access to capital resources through payment of the remaining license fee associated with the Company’s entry into a joint venture and technology license agreement with Beijing Ryzur Medical Investment Co., Ltd. On August 2, 2022, the Company entered into a Common Stock Purchase Agreement ("Purchase Agreement") with Keystone Capital Partners ("Keystone"), under which the Company at its sole discretion can direct Keystone to purchase the Company's common stock at a discount to the then current market price. Keystone is committed to purchase a minimum of 1,399,348 shares, which represents a value of approximately $2.3 million as of August 2, 2022, after application of the discount market price and a maximum of $5.0 million under the twenty-four (24) month term of the Purchase Agreement. See Note 10 - Subsequent Events, for further discussion. The Company may also undertake public or private equity offerings, obtain proceeds from exercises of outstanding warrants, debt financings, or other means. Debt financing may require the Company to pledge assets and enter into covenants that could restrict certain business activities or its ability to incur further indebtedness; and may contain other terms that are not favorable to the Company or its stockholders. Based on the Company’s cash balance of approximately $10.2 million as of June 30, 2022, committed capital from its Purchase Agreement with Keystone and its expected cash flows, the Company believes that its available cash plus committed capital will be sufficient to fund its operations for at least the next 12 months from issuance date of these financial statements.

Description of Business

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Note 1 — Description of Business

Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to orthotics and prosthetics (O&P) providers around the world, the Veterans Health Administration, and distributors in Europe and Australia. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts.

Liquidity

The Company incurred net losses of approximately $5.7 million and $5.6 million during the six months ended June 30, 2022 and 2021, respectively, and has an accumulated deficit of approximately $83.8 million and $78.1 million at June 30, 2022 and December 31, 2021, respectively. Cash used in operating activities was approximately $5.0 million and $5.5 million for the six months ended June 30, 2022 and 2021, respectively. The Company has historically funded its operations through financing activities, including raising equity and debt capital.

The Company’s operating plans are primarily focused on scaling up its operations, increasing the proportion of patients carrying commercial insurance with payers that have historically reimbursed for the Company’s products and continued work with the Centers for Medicare and Medicaid Services, or CMS, and their administrative contractors regarding reimbursement of its products. In addition, the Company believes that it has access to capital resources through payment of the remaining license fee associated with the Company’s entry into a joint venture and technology license agreement with Beijing Ryzur Medical Investment Co., Ltd. On August 2, 2022, the Company entered into a Common Stock Purchase Agreement ("Purchase Agreement") with Keystone Capital Partners ("Keystone"), under which the Company at its sole discretion can direct Keystone to purchase the Company's common stock at a discount to the then current market price. Keystone is committed to purchase a minimum of 1,399,348 shares, which represents a value of approximately $2.3 million as of August 2, 2022, after application of the discount market price and a maximum of $5.0 million under the twenty-four (24) month term of the Purchase Agreement. See Note 10 - Subsequent Events, for further discussion. The Company may also undertake public or private equity offerings, obtain proceeds from exercises of outstanding warrants, debt financings, or other means. Debt financing may require the Company to pledge assets and enter into covenants that could restrict certain business activities or its ability to incur further indebtedness; and may contain other terms that are not favorable to the Company or its stockholders.

Based on the Company’s cash balance of approximately $10.2 million as of June 30, 2022, committed capital from its Purchase Agreement with Keystone and its expected cash flows, the Company believes that its available cash plus committed capital will be sufficient to fund its operations for at least the next 12 months from issuance date of these financial statements.